earnings
confidence high
sentiment neutral
materiality 0.45
Scribe Therapeutics Q3 2026 net loss $9.9M ($0.68/sh); $174.2M cash funds operations into 1H 2029
Scribe Therapeutics, Inc.
- Net loss $9.9M ($0.68 per basic and diluted share) vs $6.5M net loss in Q2 2026; R&D $8.3M, G&A $4.2M, collaboration revenue $1.6M.
- Cash, equivalents and marketable securities $174.2M at Sept 30, 2026 vs $43.0M at June 30, after ~$140.2M net IPO/private placement proceeds; runway into 1H 2029.
- STX-1150 Phase 1 in elevated LDL-C ongoing; safety, tolerability and LDL-C data from single ascending dose expected 1H 2027; NHP data showed >50% LDL-C cut at 0.75 mg/kg for two years.
- Expanded Sanofi collaboration to include ELXR epigenetic silencing technology, adding to XE gene editing and extending Sanofi's target nomination period; no financial terms disclosed.
- July 2026 IPO upsized and priced at high end; ~$155.5M gross proceeds including underwriters' option and concurrent Sanofi private placement at the IPO price.